Inovio’s MERS vaccine, SynCon DNA vaccine, induces ‘robust and durable immune responses’ in pre-clinical testing

Inovio Pharmaceuticals, Inc. announced recently that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, More...